Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity

Medicine and Dentistry

• Metabolomics 74%
• Obesity 62%
• Glucagon-Like Peptide-1 Agonist 62%
• Liraglutide 62%
• Maturity Onset Diabetes of the Young 50%
• Clinical Study 37%
• Combination Therapy 37%
• Glucose 37%
• Roux-en-Y Gastric Bypass 37%
• Therapeutic Procedure 37%
• Lipid 25%
• Diet 25%
• 3 Hydroxybutyric Acid 25%
• Sleeve Gastrectomy 25%
• Lipidomics 25%
• Metabolome 25%
• Inpatient 25%
• Weight Loss 25%
• Triglyceride-Rich Lipoprotein 25%
• Body Weight 12%
• Triacylglycerol 12%
• Cohort Analysis 12%
• Body Mass Index 12%
• Caloric Intake 12%
• Trimethylamine 12%
• Branched Chain Amino Acid 12%
• Ketone Body 12%
• Nuclear Magnetic Resonance Spectroscopy 12%
• Oxide 12%
• Marker 12%
• Amaurosis 12%
• Obesity Medicine 12%
• Morbid Obesity 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Obesity 62%
• Glucagon Like Peptide 1 Receptor Agonist 62%
• Liraglutide 62%
• Non Insulin Dependent Diabetes Mellitus 50%
• Glucose 37%
• Lipoprotein 37%
• Lipid 25%
• Acetoacetic Acid 25%
• 3 Hydroxybutyric Acid 25%
• Triacylglycerol 12%
• Blindness 12%
• Ketone Body 12%
• Morbid Obesity 12%
• Branched Chain Amino Acid 12%
• Oxide 12%
• Trimethylamine 12%

Biochemistry, Genetics and Molecular Biology

• Metabolomics 74%
• Receptor Agonists 62%
• Lipoprotein 37%
• Weight 37%
• Calorie 25%
• Lipidomics 25%
• Glucose Level 25%
• Metabolome 25%
• Lipid 25%
• Electric Potential 12%
• Glucose 12%
• Body Mass 12%
• Body Weight 12%
• Ketone Bodies 12%
• Trimethylamine N-Oxide 12%
• Nuclear Magnetic Resonance Spectroscopy 12%
• Reduction (Chemistry) 12%
• Time 12%
• Amino Acids 12%
• Cohort Study 12%